Sano, Bristol-Myers Squibb deal

The companies reached an exclusive worldwide agreement to complete clinical testing and to market SANO's transdermal formulations of Bristol-Myers Squibb's BuSpar (buspirone HCl), a U.S.-approved drug to treat anxiety.

Bristol-Myers will complete the clinical development program for transdermal BuSpar, and is responsible for marketing the product upon regulatory approval. ...